The latest update is out from Apogee Therapeutics, Inc. (APGE).
Apogee Therapeutics, Inc. has recently elected Lisa L. Bollinger, M.D., a distinguished expert with over 30 years in drug development, as a Class II director. Dr. Bollinger, who has held significant roles at the FDA and leading biopharmaceutical companies like Merck & Co. and Amgen Inc., will serve on the Board until the 2025 Annual Meeting of Stockholders. Her considerable experience in regulatory affairs and pharmacovigilance positions her as a valuable addition to the Nominating and Corporate Governance Committee, enhancing the company’s strategic direction in the healthcare sector.
Learn more about APGE stock on TipRanks’ Stock Analysis page.
